Lineage Cell Therapeutics, Inc. (LCTX) Earnings History
Annual and quarterly earnings data from 1992 to 2025
Loading earnings history...
LCTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LCTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -251.6% | -436.5% |
| 2024 | 96.5% | -226.1% | -195.9% |
| 2023 | 92.5% | -276.5% | -240.2% |
| 2022 | 95.0% | -153.2% | -178.7% |
| 2021 | 63.4% | -1263.1% | -1104.2% |
Download Data
Export LCTX earnings history in CSV or JSON format
Free sign-in required to download data
Lineage Cell Therapeutics, Inc. (LCTX) Earnings Overview
As of May 8, 2026, Lineage Cell Therapeutics, Inc. (LCTX) reported trailing twelve-month net income of -$64M, reflecting -201.1% year-over-year growth. The company earned $-0.28 per diluted share over the past four quarters, with a net profit margin of -436.5%.
Looking at the long-term picture, LCTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $34M in fiscal 2016.
Lineage Cell Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), NTLA (-$413M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), LCTX has outperformed on profitability metrics. Compare LCTX vs FATE →
LCTX Earnings vs Peers
Earnings metrics vs comparable public companies
LCTX Historical Earnings Data (1992–2025)
34 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$64M | -241.4% | -$37M | $-0.28 | -436.5% | -251.6% |
| 2024 | -$19M | +13.4% | -$21M | $-0.09 | -195.9% | -226.1% |
| 2023 | -$21M | +18.2% | -$25M | $-0.12 | -240.2% | -276.5% |
| 2022 | -$26M | +38.9% | -$23M | $-0.15 | -178.7% | -153.2% |
| 2021 | -$43M | -108.3% | -$49M | $-0.26 | -1104.2% | -1263.1% |
| 2020 | -$21M | -76.4% | -$26M | $-0.14 | -2671.3% | -3421.3% |
| 2019 | -$12M | +74.5% | -$39M | $-0.08 | -792.2% | -2630.3% |
| 2018 | -$46M | -130.2% | -$42M | $-0.36 | -3247.9% | -2951.6% |
| 2017 | -$20M | -159.5% | -$39M | $-0.17 | -1114.7% | -2170.9% |
| 2016 | $34M | +171.4% | -$59M | $0.34 | 1490.8% | -2618.4% |
See LCTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LCTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LCTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLCTX — Frequently Asked Questions
Quick answers to the most common questions about buying LCTX stock.
Is LCTX growing earnings?
LCTX EPS fell to $-0.28, with earnings declining -201.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-64M.
What are LCTX's profit margins?
Lineage Cell Therapeutics, Inc. net margin is -436.5%, with operating margin at -251.6%. Below-average margins reflect competitive or cost pressures.
How consistent are LCTX's earnings?
LCTX earnings data spans 1992-2025. The declining earnings trend is -201.1% YoY. Historical data enables comparison across business cycles.